Somagenetix Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$2.48M
- Investors
-
6
Somagenetix General Information
Description
Operator of a biotechnology company intended to develop new cell and gene therapies to treat patients with severe inherited immune diseases. The company focuses on the discovery and development of stem cells from bone marrow and on the delivery of therapeutic genes via lentiviral vectors to compensate for inborn genetic defects, and on the transplantation of gene-corrected cells back into patients, enabling doctors to correct the underlying genetic cause of disease and cure patients with various monogenetic defects.
Contact Information
Website
www.somagenetix.comCorporate Office
- Bahnhofstrasse 1
- 8852 Altendorf
- Switzerland
Corporate Office
- Bahnhofstrasse 1
- 8852 Altendorf
- Switzerland
Somagenetix Timeline
Somagenetix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 25-Aug-2025 | $2.48M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series A) | 08-Oct-2024 | Completed | Generating Revenue | |||
| 3. Seed Round | 05-May-2022 | Completed | Startup | |||
| 2. Accelerator/Incubator | 09-Oct-2019 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
Somagenetix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Preferred shares | ||||||||
| Preferred shares | 18,177 | $1.240665 | $137.71 | $137.71 | 1x | $137.71 | 9.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Somagenetix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Somagenetix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Somagenetix Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Vi Partners | Venture Capital | Minority | ||
| Schroders Capital | Asset Manager | Minority | ||
| Verve Ventures | Venture Capital | Minority | ||
| Zürcher Kantonalbank | Asset Manager | Minority | ||
| Wyss Zurich | Accelerator/Incubator | Minority |
Somagenetix FAQs
-
When was Somagenetix founded?
Somagenetix was founded in 2018.
-
Where is Somagenetix headquartered?
Somagenetix is headquartered in Altendorf, Switzerland.
-
What is the size of Somagenetix?
Somagenetix has 10 total employees.
-
What industry is Somagenetix in?
Somagenetix’s primary industry is Biotechnology.
-
Is Somagenetix a private or public company?
Somagenetix is a Private company.
-
What is the current valuation of Somagenetix?
The current valuation of Somagenetix is .
-
What is Somagenetix’s current revenue?
The current revenue for Somagenetix is .
-
How much funding has Somagenetix raised over time?
Somagenetix has raised $16.4M.
-
Who are Somagenetix’s investors?
Vi Partners, Schroders Capital, Verve Ventures, Zürcher Kantonalbank, and Wyss Zurich are 5 of 6 investors who have invested in Somagenetix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
